Expert view: The future of cell expansion for monoclonal antibody production
There is room for improvement in the production of monoclonal antibodies; commercial production needs increased process efficiency and reduced costs.
List view / Grid view
Articles
Expert view – The Octet HTX system: enabling multi-purpose screening of therapeutic biologics during development
Current trends in the development of therapeutic biologics suggest that engineered molecules such as bispecific antibodies and antibody-drug conjugates are the future of the industry, yet despite this, monoclonal antibody (mAb) development remains a dominant focus.
Expert view: Understanding the fast-evolving immune-oncology landscape
The number of immuno-oncology active agents has seen a tremendous boost during the past three years. The 2019 global immuno-oncology pipeline consists of almost 3,900 agents, making immuno-oncology discovery very attractive.
Expert view: Promising methods in kinase screening
Kinase-mediated phosphorylation is a control point for nearly all activity within a cell, making kinases important in many diseases.
Expert view: Following mitchondrial substrate oxidation pathways to expose novel drug targets
Energy metabolism drives everything we do, so it is no surprise that the more we discover about these metabolic processes, the more we observe seamless integration with all core cellular functions.
Five recent drug target discoveries for pancreatic cancer
This article highlights some of the most recent drug target discoveries that could be used to develop and design a treatment for pancreatic cancer.
Hit-To-Lead In-Depth Focus 2019
This in-depth focus features articles on identifying new leads for neglected tropical diseases and how to develop novel peptide hits into lead compounds.
Targets In-Depth Focus 2019
The articles in this In-Depth Focus explore a novel technique for studying protein aggregation in Alzheimer's research and explain how to maximise the potential of mass spectrometry.
Screening In-Depth Focus 2019
In this In-Depth Focus are articles investigating how CROs can help to drive innovation and how CRISPR technologies could be used for drug screening purposes.
Drug Target Review – Issue 4 2019
This issue includes a discussion on the future of high-throughput screening through collaboration, an analysis of mass spectrometry as a structural biology tool and an exploration of the challenges of hit-to-lead when researching tropical diseases. Also in the issue are articles on immuno-oncology and assays.
Progression, trends and industry leaders in HIV and AIDS research
HIV is a disease still common in sub-Saharan Africa despite global research since 1982. This article delves into the trends, opportunities and key players in HIV research, exploring future possibilities for treating the disease.
How will CRISPR evolve in the future?
CRISPR is a tool used by researchers to precisely edit genes and has shown potential for treating genetic diseases. This article delves into some recent developments and explores what the future holds for CRISPR.
A novel target revealed for myelodysplastic syndrome
Researchers have discovered a potential new strategy for treating myelodysplastic syndrome, which has shown to be successful in pre-clinical trials.
SEL120: a promising CDK8 kinase inhibitor
A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
The challenges of hit-to-lead in drug discovery
A study that identified 12 novel compounds that may prove valuable against new drug targets for leishmaniasis and Chagas disease was not without complication. Here, we discuss the findings but also the challenges the researchers reported in their hit-to-lead study.
